NASDAQ:DMPI - DelMar Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$1.86 -0.39 (-17.33 %)
(As of 05/24/2019 04:00 PM ET)
Previous Close$2.25
Today's Range$1.65 - $2.09
52-Week Range$1.65 - $9.80
Volume168,549 shs
Average Volume45,707 shs
Market Capitalization$4.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63

Headlines

DelMar Pharmaceuticals (NASDAQ DMPI) News Headlines

Source:
DateHeadline
DelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q3 2019 Results - Earnings Call TranscriptDelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q3 2019 Results - Earnings Call Transcript
seekingalpha.com - May 23 at 7:42 PM
DelMar Pharma up 32% as rights offering progressesDelMar Pharma up 32% as rights offering progresses
seekingalpha.com - May 21 at 5:40 PM
DelMar Pharmaceuticals Announces Expansion of Scientific Advisory BoardDelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board
finance.yahoo.com - May 20 at 10:58 PM
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial ResultsDelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results
finance.yahoo.com - May 15 at 8:03 AM
DelMar Pharma files updated prospectus for subscription rights offeringDelMar Pharma files updated prospectus for subscription rights offering
seekingalpha.com - May 8 at 7:55 PM
DelMar Pharmaceuticals Announces 1-for-10 Reverse Stock SplitDelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split
finance.yahoo.com - May 7 at 7:19 PM
Head to Head Review: DelMar Pharmaceuticals (DMPI) vs. Emisphere Technologies (EMIS)Head to Head Review: DelMar Pharmaceuticals (DMPI) vs. Emisphere Technologies (EMIS)
www.americanbankingnews.com - May 5 at 2:43 PM
DelMar Pharma files for subscription rights offering; shares down 2% premarketDelMar Pharma files for subscription rights offering; shares down 2% premarket
seekingalpha.com - April 18 at 10:01 AM
DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Centers IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083
finance.yahoo.com - April 3 at 8:59 AM
DelMar Pharmaceuticals Inc.DelMar Pharmaceuticals Inc.
www.barrons.com - March 4 at 5:52 PM
DelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q2 2019 Results - Earnings Call TranscriptDelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - February 20 at 10:09 AM
DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBMDelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
finance.yahoo.com - February 20 at 10:09 AM
Form 8-K DelMar Pharmaceuticals, For: Feb 12 - StreetInsider.comForm 8-K DelMar Pharmaceuticals, For: Feb 12 - StreetInsider.com
www.streetinsider.com - February 13 at 9:59 AM
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial ResultsDelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results
finance.yahoo.com - February 12 at 9:34 AM
DelMar Pharmaceuticals Receives Nasdaq Listing ExtensionDelMar Pharmaceuticals Receives Nasdaq Listing Extension
finance.yahoo.com - February 7 at 9:23 AM
Form SC 13G DelMar Pharmaceuticals, Filed by: SABBY MANAGEMENT, LLC - StreetInsider.comForm SC 13G DelMar Pharmaceuticals, Filed by: SABBY MANAGEMENT, LLC - StreetInsider.com
www.streetinsider.com - November 27 at 8:00 AM
Form 8-K DelMar Pharmaceuticals, For: Nov 25 - StreetInsider.comForm 8-K DelMar Pharmaceuticals, For: Nov 25 - StreetInsider.com
www.streetinsider.com - November 27 at 8:00 AM
Consolidated Research: 2018 Summary Expectations for iKang Healthcare Group, Collectors Universe, QuickLogic ...Consolidated Research: 2018 Summary Expectations for iKang Healthcare Group, Collectors Universe, QuickLogic ...
globenewswire.com - November 25 at 8:00 AM
Consolidated Research: 2018 Summary Expectations for iKang Healthcare Group, Collectors Universe, QuickLogic, The Ultimate Software Group, Internet Gold Golden Lines, and DelMar Pharmaceuticals — Fundamental Analysis, Key Performance IndicationsConsolidated Research: 2018 Summary Expectations for iKang Healthcare Group, Collectors Universe, QuickLogic, The Ultimate Software Group, Internet Gold Golden Lines, and DelMar Pharmaceuticals — Fundamental Analysis, Key Performance Indications
finance.yahoo.com - November 23 at 8:03 AM
DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT ...DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT ...
www.prnewswire.com - November 21 at 5:24 PM
DelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q1 2019 Results - Earnings Call TranscriptDelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - November 21 at 8:00 AM
DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual MeetingDelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting
finance.yahoo.com - November 20 at 8:08 AM
DelMar Pharmaceuticals net loss improves in Q1DelMar Pharmaceuticals net loss improves in Q1
seekingalpha.com - November 14 at 8:01 AM
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial ResultsDelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results
finance.yahoo.com - November 14 at 8:01 AM
Who Owns Most Of DelMar Pharmaceuticals Inc (NASDAQ:DMPI)?Who Owns Most Of DelMar Pharmaceuticals Inc (NASDAQ:DMPI)?
finance.yahoo.com - October 16 at 5:10 PM
DelMar Announces Further Validation of the Mechanism of Action of VAL-083DelMar Announces Further Validation of the Mechanism of Action of VAL-083
finance.yahoo.com - October 10 at 8:01 AM
DelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q4 2018 Results - Earnings Call TranscriptDelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - September 26 at 8:01 AM
DelMar Pharmaceuticals reports Q4 resultsDelMar Pharmaceuticals reports Q4 results
seekingalpha.com - September 24 at 5:10 PM
DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial ResultsDelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results
finance.yahoo.com - September 24 at 9:08 AM
DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic AdvisorDelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor
www.prnewswire.com - September 4 at 8:03 AM
DelMar Pharmaceuticals appoints Oppenheimer & Co as strategic advisorDelMar Pharmaceuticals appoints Oppenheimer & Co as strategic advisor
seekingalpha.com - September 4 at 8:03 AM
DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBMDelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM
finance.yahoo.com - June 26 at 8:53 AM
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of DirectorsDelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors
finance.yahoo.com - June 25 at 10:30 AM
DelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q3 2018 Results - Earnings Call TranscriptDelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - May 31 at 8:00 AM
BRIEF-Delmar Appoints Saiid Zarrabian Full-Time President And CEOBRIEF-Delmar Appoints Saiid Zarrabian Full-Time President And CEO
www.reuters.com - May 23 at 5:33 PM
Delmar Pharma (DMPI) Names Saiid Zarrabian as Full-Time President and CEODelmar Pharma (DMPI) Names Saiid Zarrabian as Full-Time President and CEO
www.streetinsider.com - May 23 at 5:33 PM
DelMar Appoints Saiid Zarrabian to Full-Time President and CEODelMar Appoints Saiid Zarrabian to Full-Time President and CEO
finance.yahoo.com - May 22 at 8:00 AM
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial ResultsDelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results
www.prnewswire.com - May 17 at 5:49 AM
Delmar Pharma (DMPI) Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBMDelmar Pharma (DMPI) Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM
www.streetinsider.com - April 27 at 5:28 PM
DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBMDelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM
finance.yahoo.com - April 17 at 5:39 PM
DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer ResearchDelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research
finance.yahoo.com - April 16 at 9:09 AM
BRIEF-Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share ...BRIEF-Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share ...
www.reuters.com - April 15 at 5:43 PM
Today’s Research Reports on Stocks to Watch: Lipocine and DelMar PharmaceuticalsToday’s Research Reports on Stocks to Watch: Lipocine and DelMar Pharmaceuticals
finance.yahoo.com - February 28 at 8:44 AM
DelMar Pharmaceuticals (DMPI) Management on Q2 2018 Results ... - Seeking AlphaDelMar Pharmaceuticals' (DMPI) Management on Q2 2018 Results ... - Seeking Alpha
seekingalpha.com - February 22 at 8:11 AM
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year ... - PR Newswire (press release)DelMar Pharmaceuticals Announces Second Quarter Fiscal Year ... - PR Newswire (press release)
www.prnewswire.com - February 15 at 7:24 AM
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial ResultsDelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results
finance.yahoo.com - February 15 at 7:24 AM
Is DelMar Pharmaceuticals Inc (NASDAQ:DMPI) A Healthcare Industry Laggard Or Leader?Is DelMar Pharmaceuticals Inc (NASDAQ:DMPI) A Healthcare Industry Laggard Or Leader?
finance.yahoo.com - February 14 at 3:32 PM
DelMar Pharmaceuticals stock rockets after cancer treatment granted Fast Track designation - MarketWatchDelMar Pharmaceuticals' stock rockets after cancer treatment granted 'Fast Track' designation - MarketWatch
www.marketwatch.com - December 28 at 8:18 AM
A Peek Into The Markets: US Stock Futures Down; Mallinckrodt To Acquire Sucampo Pharmaceuticals - BenzingaA Peek Into The Markets: US Stock Futures Down; Mallinckrodt To Acquire Sucampo Pharmaceuticals - Benzinga
www.benzinga.com - December 26 at 9:06 AM
Delmar Pharma (DMPI) Gramted Fast Track Designation for VAL ... - StreetInsider.comDelmar Pharma (DMPI) Gramted Fast Track Designation for VAL ... - StreetInsider.com
www.streetinsider.com - December 26 at 9:06 AM
This page was last updated on 5/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel